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therapy of captopril/HCTZ in the treatment of hypertension in
Poland. METHODS: To gain data on clinical effectiveness of
analyzed therapies the clinical effectiveness analysis based on
systematic review of RCTs was conducted. Direct medical costs
regarding drug costs and ambulatory treatment, second-line
therapy, complications and adverse events valid from public
payer perspective were taken into account in the model. Costs
data were gained from National Health Fund in Poland and
medical experts from cardiology and hypertension. Modelling
method applied was a Markov model with a 32 year time
horizon. Sensitivity analyses was performed. The analysis were
done according to HTA guidelines in Poland. RESULTS: Statis-
tically signiﬁcant difference in hypertension reduction between
ramipril/HCTZ and monotherapy with ramipril or HCTZ was
revealed in favour of ramipril/HCTZ. No signiﬁcant differences
in safety proﬁle were found. No signiﬁcant differences in hyper-
tension reduction were observed in comparison to combined
therapy captopril/HCTZ but hypertension control was signiﬁ-
cantly longer for ramipril/HCTZ treatment. The analysis showed
that incremental costs per LYGs were estimated at 1,515 PLN,
6,969 PLN, 10,733 PLN for ramipril/HCTZ compared to rami-
pril, HCTZ or combined therapy captopril/HCTZ, respectively.
Incremental costs per QALY were estimated at 1,925 PLN, 8,800
PLN, 13,930 PLN when comparing ramipril/HCTZ with stan-
dard therapy of ramipril, HCTZ and captopril/HCTZ respec-
tively. Sensitivity analysis showed that the results of the analysis
are robust. CONCLUSIONS: Treatment of hypertension with
Tritace comb (ramipril/HCTZ) compared with a standard mono
therapy (ramipril, HCTZ) and with combined therapy captopril/
HCTZ is very cost-effective option from the public payer’s per-
spective in Poland. Incremental costs per LYG and per QALYs
are below the acceptable threshold for very cost-effectiveness
treatment in Poland (27,000 PLN).
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OBJECTIVES: To evaluate the cost-effectiveness of enoxaparin
compared with unfractionated heparin (UFH) or no prophylaxis
for prevention of venous thromboembolism (VTE) in hospital-
ised medical patients from the Australian hospital perspective.
METHODS: A hypothetical cohort of hospitalised medical
patients was assumed to receive prophylaxis of one of the fol-
lowing: enoxaparin 40 mg once-daily (od); UFH 5000 IU thrice-
daily (tid); UFH 5000 IU bi-daily (bid); no prophylaxis. A
decision-analytic model was constructed using clinical trial data
and local treatment algorithms. Analysis was conducted for all
medical inpatients and a subgroup of patients with ischaemic
stroke. The analysis estimated the incidence of VTE (symptom-
atic DVT and PE), adverse events (heparin-induced throm-
bocytopenia [HIT], prophylaxis and treatment-related major
bleeding), mortality and costs of prophylaxis and treatment
within 30 days and one year of initiating prophylaxis. RESULTS:
In a cohort of 10,000 patients, at 30 days the estimated number
of VTE events was 107 (enoxaparin or UFH tid), 189 (UFH bid)
and 292 (no prophylaxis). Estimated numbers of adverse events
were 54 (enoxaparin), 198 (UFH tid), 199 (UFH bid) and 49 (no
prophylaxis). Estimated total numbers of deaths attributable to
prophylaxis, VTE treatment and adverse events were 27 (enox-
aparin), 40 (UFH tid), 57 (UFH bid) and 63 (no prophylaxis).
Total costs of prophylaxis, diagnostic testing, VTE treatment and
adverse event treatment were AUS$1.1 million (enoxaparin),
AUS$1.7 million (UFH tid), A$1.9 million (UFH bid) and
AUS$1.4 million (no prophylaxis). An additional 12 (enoxaparin
or UFH tid), 21 (UFH bid) or 32 (no prophylaxis) VTE events
were incurred at one year. In patients with ischaemic stroke there
was an enhanced effect of enoxaparin versus other therapies,
with greater cost savings and incremental outcomes. CONCLU-
SIONS: Thromboprophylaxis with enoxaparin prevents VTE
events and related deaths in medical patients, and simulated
cohort analysis demonstrates its cost-saving potential when used
instead of UFH.
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OBJECTIVES: Venous thromboembolism (VTE) is a relevant
cause of morbidity and mortality in patients undergoing major
orthopaedic surgery (MOS). Thromboprophylaxis is recom-
mended in this setting and low-molecular-weight-heparins
(LMWHs) are the anticoagulant agents most frequently used.
Fondaparinux is an effective and safe alternative in this setting.
Objective of our study was to investigate the cost-effectiveness
of fondaparinux versus enoxaparin from the perspective of the
Italian National Health Service (NHS) in patients undergoing
MOS. METHODS: A decision tree model was developed in
order to compare fondaparinux with enoxaprin in extended
thromboprophylaxis of patients undergoing MOS. Probabilities
of symptomatic events were derived from the results of ran-
domized controlled trials; use of resources in common clinical
practice in Italy was evaluated by means of an “ad hoc” ques-
tionnaire administered to a panel of experts. Only direct cost of
VTE (acute treatment of events and of complications) were
included in the analysis. Cost units were derived from current
cost of drugs and from Italian National Healthcare tariffs for
tests and medical visits in 2007 (in Euros). Incremental Cost-
Effectiveness ratios were analysed at three time points: 30 days,
one year, ﬁve years. RESULTS: After 30 days of extended pro-
phylaxis fondaparinux was associated with a lower cost com-
pared with enoxaparin, leading a saving of €48.83 per patient.
At the end of the ﬁrst year after MOS, the saving is increased
to €72.13: rates of late PE and late DVT which are higher with
enoxaparin, particularly for patient undergoing total hip
replacement (which is the 34% of the population of the model),
accounted for this difference. Overall, after 5 years the saving
with fondaparinux is €74.36 per patient. Direct cost of pro-
phylaxis is higher with fondaparinux, but this is highly com-
pensated by the different rates of early DVT, early PE and
prophylaxis-related major bleeding. One-way sensitivity analy-
sis showed that results were robust to the variation in unit costs
for VTE related care or in event rates for both treatments.
CONCLUSIONS: The different rates of early and late DVT, PE
and prophylaxis-related major bleeding overbalanced the lower
cost of enoxaparin, in favour of fondaparinux. Our model sug-
gests that fondaparinux is cost-saving when compared to enox-
aparin for VTE prophylaxis in patients undergoing MOS in
Italy.
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